BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 30294924)

  • 1. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Algorithmic approach to patients presenting with heartburn and epigastric pain refractory to empiric proton pump inhibitor therapy.
    Roorda AK; Marcus SN; Triadafilopoulos G
    Dig Dis Sci; 2011 Oct; 56(10):2871-8. PubMed ID: 21512760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.
    Miyamoto M; Manabe N; Haruma K
    Intern Med; 2010; 49(15):1469-76. PubMed ID: 20686276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.
    Wu JC; Lai LH; Chow DK; Wong GL; Sung JJ; Chan FK
    Neurogastroenterol Motil; 2011 Feb; 23(2):155-60, e31. PubMed ID: 21087355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.
    Ranaldo N; Losurdo G; Iannone A; Principi M; Barone M; De Carne M; Ierardi E; Di Leo A
    Cell Death Dis; 2017 Sep; 8(9):e3040. PubMed ID: 28880273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease.
    Nojkov B; Rubenstein JH; Adlis SA; Shaw MJ; Saad R; Rai J; Weinman B; Chey WD
    Aliment Pharmacol Ther; 2008 Mar; 27(6):473-82. PubMed ID: 18194508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of improvement of impaired chemical clearance characterizes PPI-refractory reflux-related heartburn.
    Frazzoni M; Frazzoni L; Tolone S; De Bortoli N; Savarino V; Savarino E
    Am J Gastroenterol; 2018 May; 113(5):670-676. PubMed ID: 29681623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
    Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The GerdQ questionnaire and high resolution manometry support the hypothesis that proton pump inhibitor-responsive oesophageal eosinophilia is a GERD-related phenomenon.
    Savarino EV; Tolone S; Bartolo O; de Cassan C; Caccaro R; Galeazzi F; Nicoletti L; Salvador R; Martinato M; Costantini M; Savarino V
    Aliment Pharmacol Ther; 2016 Sep; 44(5):522-30. PubMed ID: 27373195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of heartburn resolution and erosive esophagitis in patients with GERD.
    Orlando RC; Monyak JT; Silberg DG
    Curr Med Res Opin; 2009 Sep; 25(9):2091-102. PubMed ID: 19601705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of baseline impedance in patients with proton pump inhibitor-refractory nonerosive reflux disease.
    Kohata Y; Fujiwara Y; Yamagami H; Tanigawa T; Shiba M; Watanabe K; Watanabe T; Tominaga K; Arakawa T
    J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():36-40. PubMed ID: 25827802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy.
    Kahrilas PJ; Jonsson A; Denison H; Wernersson B; Hughes N; Howden CW
    Gut; 2014 May; 63(5):720-6. PubMed ID: 23831734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease.
    Niu XP; Yu BP; Wang YD; Han Z; Liu SF; He CY; Zhang GZ; Wu WC
    World J Gastroenterol; 2013 May; 19(20):3124-9. PubMed ID: 23716993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convenient Method of Measuring Baseline Impedance for Distinguishing Patients with Functional Heartburn from those with Proton Pump Inhibitor-Resistant Endoscopic Negative Reflux Disease.
    Yoshimine T; Funaki Y; Kawamura Y; Tamura Y; Izawa S; Ebi M; Ogasawara N; Murotani K; Sasaki M; Kasugai K
    Digestion; 2019; 99(2):157-165. PubMed ID: 30179879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease.
    Zerbib F; Belhocine K; Simon M; Capdepont M; Mion F; Bruley des Varannes S; Galmiche JP
    Gut; 2012 Apr; 61(4):501-6. PubMed ID: 21997546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-center retrospective study on epidemiological and Traditional Chinese Medicine syndrome characteristics of 21010 patients with reflux/heartburn symptoms.
    Yanping T; Peicai LI; Xi L; Lei L; Yanxia G; Xiaodong W; Lina L; Li Y
    J Tradit Chin Med; 2023 Jun; 43(3):574-581. PubMed ID: 37147760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histomorphological differentiation of non-erosive reflux disease and functional heartburn in patients with PPI-refractory heartburn.
    Kandulski A; Jechorek D; Caro C; Weigt J; Wex T; Mönkemüller K; Malfertheiner P
    Aliment Pharmacol Ther; 2013 Sep; 38(6):643-51. PubMed ID: 23895770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.